Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Rangaswamy Govindarajan

Concepts (127)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colonic Neoplasms
3
2016
158
0.780
Why?
Anus Neoplasms
1
2018
24
0.600
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2020
1000
0.520
Why?
Bone Marrow Neoplasms
1
2015
13
0.510
Why?
Embolism
1
2015
20
0.510
Why?
Gene Regulatory Networks
1
2016
106
0.490
Why?
Carcinoma, Squamous Cell
1
2018
326
0.480
Why?
Tumor Lysis Syndrome
1
2014
6
0.480
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2014
46
0.460
Why?
Neoplasm Recurrence, Local
1
2018
629
0.450
Why?
Pyrazoles
1
2014
111
0.440
Why?
Pyrimidines
1
2014
191
0.430
Why?
Angiogenesis Inhibitors
2
2006
183
0.420
Why?
Clinical Trials as Topic
5
2019
486
0.410
Why?
Actinomycosis
1
2012
10
0.410
Why?
Biliary Tract Diseases
1
2012
13
0.410
Why?
Salvage Therapy
1
2013
137
0.410
Why?
Bile Duct Neoplasms
1
2012
27
0.400
Why?
Stomach Neoplasms
1
2015
189
0.400
Why?
Prognosis
6
2019
1978
0.370
Why?
Gene Expression Profiling
1
2016
1025
0.370
Why?
Benzenesulfonates
2
2011
10
0.370
Why?
Middle Aged
12
2020
12611
0.360
Why?
Carcinoma, Hepatocellular
1
2013
195
0.350
Why?
Stroke
1
2015
495
0.350
Why?
Pyridines
2
2011
131
0.330
Why?
Liver Neoplasms
1
2013
326
0.330
Why?
Colorectal Neoplasms
2
2003
260
0.320
Why?
Aged, 80 and over
6
2018
3226
0.290
Why?
Heparin
1
2007
91
0.280
Why?
Drug Industry
1
2007
38
0.280
Why?
Thrombocytopenia
1
2007
81
0.270
Why?
Communication Barriers
1
2007
31
0.270
Why?
Hypertensive Encephalopathy
1
2006
3
0.270
Why?
raf Kinases
1
2006
4
0.270
Why?
Thiazolidinediones
1
2007
82
0.270
Why?
Aged
9
2020
9741
0.250
Why?
Skin
1
2007
388
0.240
Why?
Anticoagulants
1
2007
256
0.240
Why?
Thrombosis
1
2007
250
0.230
Why?
Adult
9
2020
13577
0.230
Why?
Enzyme Inhibitors
1
2006
377
0.230
Why?
Female
11
2020
27081
0.220
Why?
Survival Rate
2
2018
909
0.210
Why?
Prostatic Neoplasms
1
2007
384
0.210
Why?
Humans
16
2020
50503
0.210
Why?
Follow-Up Studies
3
2019
2242
0.200
Why?
Camptothecin
1
2002
15
0.200
Why?
Male
10
2020
25907
0.200
Why?
Antineoplastic Agents, Phytogenic
1
2002
66
0.190
Why?
Lung Neoplasms
1
2007
601
0.180
Why?
Diabetes Mellitus, Type 2
1
2007
519
0.180
Why?
Oximes
1
2020
12
0.180
Why?
Pyrimidinones
1
2020
19
0.180
Why?
Pyridones
1
2020
34
0.170
Why?
Thalidomide
1
2002
378
0.170
Why?
Imidazoles
1
2020
127
0.170
Why?
Cholangiocarcinoma
2
2011
25
0.160
Why?
Protein Kinase Inhibitors
1
2020
204
0.160
Why?
Survival Analysis
3
2020
661
0.150
Why?
Antineoplastic Agents
2
2019
1172
0.140
Why?
Melanoma
1
2020
280
0.140
Why?
Neoplasm Staging
2
2013
746
0.130
Why?
Combined Modality Therapy
1
2018
641
0.130
Why?
Severity of Illness Index
1
2019
978
0.130
Why?
Antibodies, Monoclonal
1
2019
462
0.120
Why?
Skin Neoplasms
1
2020
491
0.120
Why?
Gene Amplification
1
2015
56
0.120
Why?
Adenine
1
2014
31
0.120
Why?
Genes, myc
1
2015
32
0.120
Why?
Polycomb Repressive Complex 2
1
2015
46
0.120
Why?
Retrospective Studies
3
2018
6263
0.120
Why?
United States
3
2019
4955
0.110
Why?
Piperidines
1
2014
99
0.110
Why?
Gene Deletion
1
2015
261
0.110
Why?
Registries
3
2007
563
0.110
Why?
Treatment Outcome
4
2020
5283
0.110
Why?
Quinazolines
1
2013
32
0.110
Why?
Leukemia, Myeloid, Acute
1
2015
181
0.110
Why?
Actinomyces
1
2012
10
0.100
Why?
Gene Expression Regulation, Neoplastic
1
2016
833
0.100
Why?
Endoscopy, Gastrointestinal
1
2012
75
0.100
Why?
Comorbidity
2
2019
623
0.090
Why?
Gallbladder Neoplasms
1
2011
7
0.090
Why?
Antibodies, Monoclonal, Humanized
1
2013
226
0.090
Why?
Phenylurea Compounds
2
2011
15
0.090
Why?
Niacinamide
2
2011
23
0.090
Why?
Incidence
2
2019
1032
0.090
Why?
Neoplasms
1
2019
1251
0.080
Why?
Necrosis
1
2007
174
0.070
Why?
Drugs, Investigational
1
2007
14
0.070
Why?
Causality
1
2007
47
0.070
Why?
Hospitals, University
1
2007
77
0.070
Why?
Confidence Intervals
1
2007
154
0.070
Why?
Neoplasm Metastasis
2
2011
232
0.070
Why?
Age Distribution
1
2007
170
0.070
Why?
Probability
1
2007
164
0.070
Why?
Tomography, X-Ray Computed
1
2012
1164
0.070
Why?
United States Food and Drug Administration
1
2007
90
0.070
Why?
Anti-Bacterial Agents
1
2012
745
0.070
Why?
Medical Oncology
1
2007
98
0.060
Why?
Syndrome
1
2006
240
0.060
Why?
Patient Selection
1
2007
259
0.060
Why?
Publication Bias
1
2005
11
0.060
Why?
Editorial Policies
1
2005
11
0.060
Why?
Periodicals as Topic
1
2005
58
0.060
Why?
Dose-Response Relationship, Drug
1
2007
1372
0.050
Why?
Risk Assessment
1
2007
1270
0.050
Why?
MAP Kinase Kinase Kinases
1
2020
19
0.040
Why?
Socioeconomic Factors
1
2003
591
0.040
Why?
Proto-Oncogene Proteins B-raf
1
2020
80
0.040
Why?
Mutation, Missense
1
2020
103
0.040
Why?
Drug Administration Schedule
1
2020
370
0.040
Why?
Trisaccharides
1
2019
1
0.040
Why?
Premedication
1
2019
17
0.040
Why?
Administration, Oral
1
2020
434
0.040
Why?
Magnetic Resonance Imaging
1
2006
1548
0.040
Why?
Infusions, Intravenous
1
2019
213
0.040
Why?
Antibodies
1
2019
153
0.040
Why?
Health Services Accessibility
1
2003
424
0.040
Why?
Disease Management
1
2019
178
0.040
Why?
Arkansas
1
2003
1985
0.030
Why?
Adolescent
1
2007
6443
0.030
Why?
In Situ Hybridization, Fluorescence
1
2015
231
0.030
Why?
Polymorphism, Single Nucleotide
1
2015
475
0.020
Why?
Young Adult
1
2020
4102
0.020
Why?
Disease-Free Survival
1
2011
444
0.020
Why?
Govindarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description